SBRT for long bone mets
- 111 pts 114 mets
- 84 femur, 26 humerus, 4 tibia
- most common doses 30-50 Gy in 5Fx
👉 2a fracture: 6.1%
👉 2a local failure: 7.2%
👉 extraosseous disease sig. associated with fracture & local failure
👍THX to all collaborators!
sciencedirect.com/science/articl…
TACE vs. SBRT for HCC: randomized phase II TRENDY trial
- stoped early due to poor a accrual
- all endpoints significantly or numerically better after SBRT
👉 time to progression 19 vs 12 mo
👉 median OS 44 vs 37 mo
👉2a local control 100% vs 44%
CONGRATS
Will all radiotherapy be delivered in max 5 fractions only?
Safe the date for virtual symposium (5 sessions of 50 min over 5 weeks): breast, prostate, lung, rectal and pancreatic cancer
Faculty: C Rödel, M Brunt, N van As, M Hawkins, S Senan
Registration open soon
#radonc
What is the "true" prevalence of oligometastatic disease?
▶️ Unbiased screening n=7000 PET scans acquired @Unispital_USZ
▶️ 55% (!) of all M+ PET scans are OMD
▶️ 50% with only n=1 met
▶️ c-MRI important for staging
👉 High clinical & scientific relevance
redjournal.org/article/S0360-…
Fresh from ASCO GU:
PACE-A trial reporting for the first time a randomized comparison of SBRT vs prostatectomy for localised prostate cancer
- improved urinary and sexual function after SBRT
- increased bowel symptoms after SBRT
CONGRATS to @nickva1 and study team !
Consequence to me:
👉 WE need to initiate and tell the stories about the benefits of modern Radiation Oncology as an important pillar of interdisciplinary cancer care
👉 we CANNOT expect others doing so
👉 we = all #radonc@ESTRO_RT@ASTRO_org@ISRSy@the_RSS …
Radiotherapy sentiment in @nytimes is eye-opening. Since 2009, over half of articles show negative bias towards RT, while only 1/4 are positive. Despite major advancements in tech like MR-Linac, adaptive RT, & heavy ions, media celebration is scarce.
thegreenjournal.com/article/S0167-…
1/7
COAST: Durvalumab alone or in combination with Oleclumab or Monalizumab in unresectable stage III NSCLC after RCT
ORR: 17.9 % vs 30.0% 35.5%
12 mo PFS: 34% vs 63% vs 73%
👉 promising data to go beyond PACIFIC
#radoncascopubs.org/doi/pdf/10.120…
Full publication of randomised Scandinavian dose escalation trial for LS SCLC
45Gy / 30 Fx / 3 weeks vs 60Gy / 40 Fx / 4 weeks
⬆️ 2a OS 74.2% vs 48.1%
⬆️ Med OS 37.2 mo vs 22.6 mo
↗️ Med PFS 18.6 mo vs 10.9 mo (p=0.13)
➡️ Grade 3+ toxicity and SAEs
#radonctinyurl.com/ryrfztj2
Safety of SBRT for max 5 oligometastases: SABR-5 study
- n=281 pts, in 31% with > 1 oligometastasis
- grade 3+ SBRT toxicity <5%
- grade 2+ SBRT toxicity 18.6%
👉 I do not know any (local) treatment in metastatic pts with such a favorable safety profile !
ja.ma/3rgIV8b
Single fraction 8Gy vs SBRT 20Gy for painful bone mets, n=126, mostly non-spine #ESTRO23
Complete pain response at 1 mo primary endpoint
👉 no difference at 1 mo
👉 improved in per protocol analysis after 3mo
👉 no increased toxicity
PATIENT SELECTION IS KEY
